The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Chemotherapy first, followed by chemoradiation (CRT) and then surgery, in the management of locally advanced rectal cancer (LARC).
Andrea Cercek
Research Funding - Lorus
Karyn A. Goodman
No relevant relationships to disclose
Carla Hajj
No relevant relationships to disclose
Emily Weisberger
No relevant relationships to disclose
Neil Howard Segal
No relevant relationships to disclose
Diane Lauren Reidy
No relevant relationships to disclose
Zsofia Kinga Stadler
No relevant relationships to disclose
Abraham Jing-Ching Wu
No relevant relationships to disclose
Martin R. Weiser
No relevant relationships to disclose
Philip Paty
No relevant relationships to disclose
Jose G. Guillem
No relevant relationships to disclose
Garrett Michael Nash
No relevant relationships to disclose
Larissa K. F. Temple
No relevant relationships to disclose
Julio Garcia-Aguilar
No relevant relationships to disclose
Leonard Saltz
Consultant or Advisory Role - Bayer; Genentech/Roche; Sanofi (U)
Research Funding - Bayer; Genentech/Roche; Immunomedics; Lorus; Taiho Pharmaceutical